Integrating interferon gamma receptor pathways, antigenicity, and immune contexture as predictors of immunotherapeutic strategies for mucosal melanomas

Read full text
Authors: Matilde Monti, Sara Picinoli, Anna Bozzola, Marco Ferrari, Mattia Bugatti, Irene Pezzali, Marco Carlomagno, Giada Carta, Matteo Orlandi, Giacomo Lora, Luisa Benerini Gatta, Francesco Missale
+18 more Giorgia Ferrari, Valentina Baldazzi, Sara Rezzola, Giovanna Tabellini, Silvia Parolini, Marcello Manfredi, Veronica De Giorgis, Emílio Marengo, Mario Turri-Zanoni, Piero Nicolai, Francesca Consoli, Davide Lombardi, Paolo Martini, Jinglun Li, Obi Griffith, Malachi Griffith, Marzia Rossato, William Vermi
Cited by: 2
References: 54

Abstract

BACKGROUND: Mucosal melanomas (MM) arise from mucosal melanocytes at various anatomical sites. These tumors are rare, highly aggressive, and often associated with poor outcomes. Current treatments, including immune checkpoint inhibitors, show limited efficacy in advanced disease. Compared with cutaneous melanomas, there is a lack of data on the immunogenicity and interferon (IFN)-γ sensitivity of MM. In this study, we examined these features in sino-nasal melanomas (SN-MM) cell lines and clinical samples using microscopy and functional genomics. METHODS: The immune contexture of SN-MM was analyzed by immunohistochemistry on 48 tumor biopsies. RNA sequencing and mass spectrometry-based proteomic approaches were used to study the IFN-γ receptor (IFNGR) pathways in five patient-derived SN-MM cell lines. Moreover, their IFN-γ sensitivity, in terms of cell viability, IFNGR/JAK/STAT signaling pathway and IFN-γ inducible proteins, was evaluated by flow cytometry and immunoblots. Neoantigen prediction was performed through integrated whole exome sequencing and RNA-sequencing analysis using pVAC-Seq. Immune effector functions were evaluated in co-culture in vitro assays. RESULTS: SN-MM tumors are mainly immune "desert" with few tumor-infiltrating lymphocytes and contain immunosuppressive macrophages, features linked to poor prognosis; moreover, tumor cells are largely CD274/programmed death-ligand 1 negative. SN-MM cell lines express transcripts for melanocytic and cancer testis antigens; moreover, sequencing analysis identified a repertoire of high-confidence neoantigens, including candidates derived from recurrently mutated oncogenic drivers. Functional assays revealed that SN-MM cells are susceptible to NK cell-mediated killing. In terms of IFN-γ sensitivity, SN-MM cells show normal surface expression of IFNGR and maintain the integrity of the IFNGR/JAK/STAT signaling pathway. Transcriptomic and proteomic analyses demonstrate that SN-MM cell lines, as a group, respond to IFN-γ by upregulating genes involved in immune recognition and antigen presentation. In 60% of SN-MM lines, IFN-γ also induces cytotoxic and anti-proliferative effects, the release of CXCL10 and upregulation of CD274/PD-L1. The remaining SN-MM cell lines, characterized by poor differentiation, show refractoriness to these effects. CONCLUSIONS: SN-MM displays an immune-desert phenotype yet retains intrinsic immunogenicity. Most tumors preserve functional IFN-γ signaling, while poorly differentiated cells show resistance to IFN-γ-mediated effects. These findings underscore heterogeneity in immune responsiveness and support functional immune profiling to refine immunotherapy strategies in MM.

Fields of Study & Subjects

Cutaneous Melanoma Detection and Management Cancer Immunotherapy and Biomarkers Melanoma and MAPK Pathways

Publication details

Journal / source
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Volume
14
Issue
3
Pages
e012222–e012222
Publication date
1 March 2026
Language
EN